When you have advanced prostate cancer: What living with the disease looks like
When You Have Advanced Prostate Cancer: What Life Looks Like
Healfromzero.com – When you have advanced prostate cancer, daily life takes on new meaning. Dr. Jamin Brahmbhatt, a urologist and robotic surgeon at Orlando Health who also teaches at the University of Central Florida’s College of Medicine, observes this reality regularly. He explains that patients frequently ask one question above all others.
“How long do I have to live?” When I tell a patient he has prostate cancer, this is usually what he asks me first.
Understanding the Prognosis
Men with early-stage or low-grade disease receive considerable reassurance from their doctors. The five-year relative survival rate exceeds 99 percent when treatment is administered. In straightforward terms, most men will not die from low-grade prostate cancer. Yet once the malignancy extends beyond the prostate gland into bones and other organs, prognosis becomes considerably more complex.
Recent developments have transformed how advanced prostate cancer is managed. Improved imaging technologies, novel pharmaceutical options, and the strategic deployment of combination therapies have extended lifespans for countless patients. Former President Joe Biden recently shared updates regarding his own journey with the condition.
In a video released on July 15, Biden provided information about his ongoing treatments, noting that progress has been favorable. His official announcement came in May 2025, when he revealed he had an aggressive variant of prostate cancer that had metastasized to his skeletal system. Since that announcement, he has continued hormone therapy, finished a radiation course, and maintained visibility in public life.
Real Stories and Statistics
Biden’s diagnosis sparked renewed interest in prostate cancer screening protocols and therapeutic approaches. More than a year has passed since his announcement, offering valuable insight into how treatment has evolved and what hope exists for men navigating this disease.
Dr. Brahmbhatt recently encountered a patient whose experience mirrors what many individuals face today. This man received his diagnosis three years prior, at which point cancer had already spread to numerous locations within his bones. Despite this, he has enjoyed cruises, traveled alongside family members, and dedicated weekend time to caring for his grandchildren.
He experiences fatigue more readily and cannot tend to his garden as he once did. Nevertheless, he remains alive and views each day as a gift. His story, alongside Biden’s public journey, illustrates contemporary life with metastatic prostate cancer.
Many patients search online for survival statistics without fully understanding their limitations. The American Cancer Society reports that five-year relative survival exceeds 99 percent when cancer remains confined to or near the prostate. That percentage falls to 38 percent when the disease reaches distant body regions. However, this latter figure derives from data collected about men treated several years ago.
Older statistics do not capture the full impact of contemporary treatments. They also fail to consider individual factors such as age, general health status, and personal response to therapy. Survival numbers describe populations rather than predicting outcomes for single individuals.
Three specific details about Biden’s condition help clinicians assess aggressiveness and determine management strategies. His cancer carries a Gleason score of 9, has spread to his bones, and remains classified as hormone-sensitive. Pathologists assign Gleason scores after examining biopsy specimens, with values typically ranging from 6 to 10. Higher scores indicate more aggressive disease, placing a score of 9 within the most severe category.
When prostate cancer metastasizes, bones represent the most frequent destination—particularly the spine, pelvis, and ribs. The disease can also reach organs including the lungs and liver. Once distant spread occurs, complete cure becomes unlikely, though treatment can effectively slow progression for many years.
The approach to therapy has shifted substantially over the past decade. Rather than reserving certain treatments for later stages, physicians now deploy their most effective options early. Historically, doctors initiated hormone therapy through testosterone-lowering injections and waited before introducing additional interventions. Today, those injections frequently combine from the outset with newer hormone-blocking medications and sometimes chemotherapy.
These combination strategies have contributed significantly to extended survival and represent one of the most important therapeutic advances of recent years. Patients’ outlooks ultimately depend on specific characteristics of their cancer and how well they respond to available treatments.